Table 1.

Baseline characteristics of a cohort of new users of H2 blockers, and new users of PPI

Baseline Characteristics		H2 Blockers (n=20,270)	PPI (n=173,321)	P Value
Age (SD)		55.40 (12.81)	56.85 (11.85)	P<0.001
Baseline eGFR in ml/min per 1.73 m2 (SD)		86.98 (15.88)	86.56 (15.67)	P<0.001
Race	White (%)	15,937 (78.62)	137,174 (79.14)	P=0.01
	Black (%)	3,784 (18.67)	32,018 (18.47)
	Other (%)	549 (2.71)	4,129 (2.38)
Sex	Male (%)	18,929 (93.38)	161,259 (93.04)	P=0.07
	Female (%)	1,341 (6.62)	12,062 (6.96)
Diabetes mellitus (%)		8,923 (44.02)	72,309 (41.72)	P<0.001
Hypertension (%)		15,814 (78.02)	136,782 (78.92)	P<0.01
Chronic lung disease (%)		7,951 (39.23)	66,955 (38.63)	P=0.10
Peripheral artery disease (%)		5,009 (24.71)	31,311 (18.07)	P<0.001
Cardiovascular disease (%)		8,459 (41.73)	71,807 (41.43)	P=0.41
Cerebrovascular disease (%)		4,596 (22.67)	26,457 (15.26)	P<0.001
Dementia (%)		5,058 (24.95)	32,380 (18.68)	P<0.001
Hyperlipidemia (%)		14,785 (72.94)	127,463 (73.54)	P=0.07
Hepatitis C (%)		1,198 (5.91)	14,892 (8.59)	P<0.001
HIV (%)		55 (0.27)	678 (0.39)	P<0.01
Gastroesophageal reflux disease (%)		3,767 (18.58)	86,804 (50.08)	P<0.001
Upper gastrointestinal tract bleeding (%)		246 (1.21)	7,898 (4.56)	P<0.001
Ulcer disease (%)		666 (3.29)	26,228 (15.13)	P<0.001
H. pylori infection (%)		22 (0.11)	4,052 (2.34)	P<0.001
Barrett esophagus (%)		15 (0.07)	3,207 (1.85)	P<0.001
Achalasia (%)		1 (0.00)	214 (0.12)	P<0.001
Stricture (%)		33 (0.16)	2,299 (1.33)	P<0.001
Esophageal adenocarcinoma (%)		3 (0.01)	291 (0.17)	P<0.001
Years of follow-up (IQR)		5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	P<0.001
Days of having related prescription during follow-up (IQR)		90 (30, 270)	450 (90, 1260)	P<0.001

IQR, interquartile range.